Oddo BHF Asset Management Sas Invests $35.06 Million in Astrazeneca Plc $AZN

Oddo BHF Asset Management Sas purchased a new position in shares of Astrazeneca Plc (NYSE:AZN) in the 4th quarter, Holdings Channel reports. The firm purchased 199,779 shares of the company’s stock, valued at approximately $35,061,000. Astrazeneca comprises approximately 1.3% of Oddo BHF Asset Management Sas’ holdings, making the stock its 15th largest holding.

Several other hedge funds also recently made changes to their positions in the business. Visionary Wealth Advisors grew its stake in shares of Astrazeneca by 1.5% during the 4th quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock worth $737,000 after acquiring an additional 60 shares in the last quarter. Kestra Investment Management LLC grew its stake in shares of Astrazeneca by 1.9% during the 4th quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock worth $595,000 after acquiring an additional 63 shares in the last quarter. Luken Investment Analytics LLC grew its stake in shares of Astrazeneca by 4.3% during the 4th quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock worth $274,000 after acquiring an additional 64 shares in the last quarter. Addison Advisors LLC grew its stake in shares of Astrazeneca by 3.9% during the 4th quarter. Addison Advisors LLC now owns 1,736 shares of the company’s stock worth $305,000 after acquiring an additional 65 shares in the last quarter. Finally, Western Wealth Management LLC grew its stake in shares of Astrazeneca by 2.5% during the 4th quarter. Western Wealth Management LLC now owns 2,887 shares of the company’s stock worth $507,000 after acquiring an additional 71 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

Astrazeneca Stock Down 0.8%

Shares of NYSE AZN opened at $177.36 on Tuesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. Astrazeneca Plc has a 52 week low of $137.23 and a 52 week high of $212.71. The stock has a market capitalization of $275.07 billion, a P/E ratio of 26.63, a PEG ratio of 1.55 and a beta of 0.25. The stock’s fifty day moving average is $188.74 and its 200 day moving average is $186.10.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. Sell-side analysts forecast that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AZN has been the subject of several research reports. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Astrazeneca in a report on Monday, June 8th. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Finally, TD Cowen reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.